June 12, 2024
8:00 a.m. – 12:00 p.m. EST
Meets DEA training requirements
During May 2020–April 2021, the estimated number of drug overdose deaths in the United States exceeded 100,000 over a 12-month period for the first time. Medications for Opioid Use Disorder (MOUD), like Buprenorphine, methadone, and naltrexone have been proven to reduce overdose and death and providers that hold a DEA license with Schedule III Authority can prescribe Buprenorphine. Ensuring prescribers have the knowledge to initiate MOUD is imperative to helping patients with opioid use disorder. Q&A and discussion to follow.
Financial Incentive:
BCBSM will provide a $250 incentive to Primary Care Providers (Physicians and Advanced Practice Professionals) who attend this MOUD training. The incentive will be limited to the first 250 registered primary care providers, so please register early to ensure a spot.
4 CME Credits Pending (4.0 hours)
- Meets DEA Training Requirements
Learning Objectives:
- Understand the basics of the neurobiology of addiction
- Understand the basic pharmacodynamics of buprenorphine
- Describe the diagnosis, intake, buprenorphine induction of a patient with OUD.
- Understand how to manage acute and chronic pain for patients with opioid use disorder with a specific emphasis on using buprenorphine for pain management
- Describe key principles in outpatient management of patients with OUD
Presenters:
- Sheba Sethi, MD
- Jonathan Morrow, MD
Who should take this training:
- Physicians
- Nurse Practitioners
- Physician Assistants